Literatur
-
1
Brenner B M, Cooper M E, de
Zeeuw D, Keane W F, Mitch W E, Parving H H, Remuzzi G, Snapinn S M, Zhang Z, Shahinfar S. RENAAL Study Investigators .
Effects
of losartan on renal and cardiovascular outcomes in patients with
type 2 diabetes and nephropathy.
N Engl J Med.
2001;
345
861-869
-
2
Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, Hansson L, Neal B, Rodgers A, Ni M hurchu
C, Clark T.
World Health
Organization-International Society of Hypertension Guidelines for
the management of hypertension. Guidelines sub-committee of the
World Health Organization.
Clin Exp Hypertens.
1999;
21
1009-1060
-
3 Deutsche Diabetes-Gesellschaft .Evidenzbasierte
Diabetes-Leitlinie DDG. Management der Hypertonie beim
Patienten mit Diabetes mellitus 2000
-
4
Guidelines Subcommittee .
World
Health Organisation - International Society of Hypertension
Guidelines for the Management of Hypertension.
J Hypertens.
1999;
17
151-183
-
5
Hansson L, Lindholm L H, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg B E, Wester P O, Bjorck J E.
Effect of angiotensin-converting-enzyme
inhibition compared with conventional therapy on cardiovascular
morbidity and mortality in hypertension: the Captopril Prevention
Project (CAPPP) randomised trial.
Lancet.
1999;
353
611-616
-
6
Hypertension in Diabetes Study
Group .
Hypertension in Diabetes Study (HDS): I. Prevalence
of hypertension in newly presenting type 2 diabetic patients and
the association with risk factors for cardiovascular and diabetic
complications.
J Hypertens.
1993;
11
309-317
-
7
Lewis E J, Hunsicker L G, Clarke W R, Berl T, Pohl M A, Lewis J B, Ritz E, Atkins R C, Rohde R, Raz I. Collaborative
Study Group .
Renoprotective effect of the angiotensin-receptor
antagonist irbesartan in patients with nephropathy due to type 2
diabetes.
N Engl J Med.
2001;
345
851-860
-
8
Lindholm L H, Ibsen H, Dahlof B, Devereux R B, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen S E, Kristiansson K, Lederballe-Pedersen O, Nieminen M S, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S ;. The LIFE Study
Group .
Cardiovascular morbidity and mortality in patients
with diabetes in the Losartan Intervention For Endpoint reduction
in hypertension study (LIFE): a randomised trial against atenolol.
Lancet.
2002;
359
1004-1010
-
9
Parving H H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P ;. Irbesartan in Patients
with Type 2 Diabetes and Microalbuminuria Study Group .
The
effect of irbesartan on the development of diabetic nephropathy
in patients with type 2 diabetes.
N Engl J Med.
2001;
345
870-878
-
10
Tuomilehto J, Rastenyte D, Birkenhager W H, Thijs L, Antikainen R, Bulpitt C J, Fletcher A E, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R.
Effects
of calcium-channel blockade in older patients with diabetes and
systolic hypertension. Systolic Hypertension in Europe Trial Investigators.
N
Engl J Med.
1999;
340
677-684
-
11
UK Prospective Diabetes Study
Group .
Efficacy of atenolol and captopril in reducing risk
of macrovascular and microvascular complications in type 2 diabetes:
UKPDS 39.
BMJ.
1998;
317
713-720
-
12
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.
Effects of an angiotensin-converting-enzyme
inhibitor, ramipril, on cardiovascular events in high-risk patients. The
Heart Outcomes Prevention Evaluation Study Investigators.
N
Engl J Med.
2000;
342
145-153
Autor
Prof. Dr. H. Hauner
Klinische Abteilung, Deutsches Diabetes-Forschungsinstitut an
der Heinrich-Heine-Universität Düsseldorf
Auf’m
Hennekamp 65
40225 Düsseldorf
Phone: 0211/33821
Fax: 0211/3382339
E-Mail:hauner@ddfi.uni-duesseldorf.de
